Cell No. : Cell Name RCB5962 : HUDEP-2-CY1  update : 2023/07/12
Comment			Currently not ready.
Comment from the depositor			A derivative cell line of HUDEP-2 in which thalassemia mutations are introduced, i.e., homozygous for the HBB IVSI-110 (G>A) mutation (HGVS name; HBB:c.93-21G>A).
Terms and conditions
Remarks
Order Form
			Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
	Basic information	Expected time	Upon a request we will start preparation. Contact us: cellkitaku.brc@riken.jp
Reference information		Reference	2
		User's Publication	0

Top

Reference

18128  Papaioannou NY, Patsali P, Naiisseh B, Papasavva PL, Koniali L, Kurita R, Nakamura Y, Christou S, Sitarou M, Mussolino C, Cathomen T, Kleanthous M, Lederer CW.  High-efficiency editing in hematopoietic stem cells and the HUDEP-2 cell line based on in vitro mRNA synthesis  Front Genome Ed  2023  5:1141618  PubMed ID: 36969374   DOI: 10.3389/fgeed.2023.1141618

18129  Papasavva P, Kleanthous M, Lederer CW.  Rare Opportunities: CRISPR/Cas-Based Therapy Development for Rare Genetic Diseases  Mol Diagn Ther  2019  23(2):201-222  PubMed ID: 30945166   DOI: 10.1007/s40291-019-00392-3

Top

User's Publication